H. Lundbeck Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Deborah Dunsire

Chief Executive Officer (CEO)

kr.56.6m

Compensación total

Porcentaje del salario del CEO	17.5%
Permanencia del CEO	3.9yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	1.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Deborah Dunsire en comparación con los beneficios de H. Lundbeck?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2022	n/a	n/a	kr.1b
Dec 31 2021	kr.57m	kr.10m	kr.1b
Sep 30 2021	n/a	n/a	kr.2b
Jun 30 2021	n/a	n/a	kr.2b
Mar 31 2021	n/a	n/a	kr.2b
Dec 31 2020	kr.26m	kr.10m	kr.2b
Sep 30 2020	n/a	n/a	kr.904m
Jun 30 2020	n/a	n/a	kr.1b
Mar 31 2020	n/a	n/a	kr.2b
Dec 31 2019	kr.21m	kr.9m	kr.2b
Sep 30 2019	n/a	n/a	kr.3b
Jun 30 2019	n/a	n/a	kr.3b
Mar 31 2019	n/a	n/a	kr.4b
Dec 31 2018	kr.14m	kr.3m	kr.4b

Compensación vs. Mercado: La compensación total ($USD7.87M) de Deborah está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD8.42M).

Compensación vs. Ingresos: La compensación de Deborah ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Deborah Dunsire (60 yo)

3.9yrs

Permanencia

kr.56,600,000

Compensación

Dr. Deborah Dunsire, M.D. serves as Director at Syros Pharmaceuticals, Inc. since September 09, 2021. She serves as Chief Executive Officer and President at H. Lundbeck A/S since September 1, 2018 and serv...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Deborah Dunsire	President & CEO	3.9yrs	kr.56.60m	sin datos
Jacob Tolstrup	Executive VP of Commercial Operations & Chief Commercial Officer	4.8yrs	kr.8.70m	0% DKK 0
Lars Bang	Executive Vice President of Product Development & Supply	3.6yrs	kr.9.00m	0% DKK 0
Per Luthman	Executive Vice President of Research & Development	3.6yrs	kr.8.40m	0% DKK 0
Bjorn Mogensen	Senior Vice President Group Finance	no data	sin datos	sin datos
Tarek Samad	Senior VP & Head of Research	1.3yrs	sin datos	sin datos
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	sin datos	sin datos
Elise Hauge	Executive Vice President of People & Communication	2.9yrs	sin datos	0% DKK 0
Ole Chrintz	Senior Vice President of International Markets	no data	sin datos	sin datos
Keld Jorgensen	Executive Vice President of Corporate Strategy & Business Development	3.4yrs	sin datos	sin datos
Rupert Sandbrink	Senior VP & Head of Clinical Development	less than a year	sin datos	sin datos
Bjørn Grønning	Vice President of Clinical Research Neurology	no data	sin datos	sin datos

3.5yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HLUY.Y se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeremy Levin	Independent Director	5.6yrs	sin datos	sin datos
Lars Rasmussen	Independent Chairman	9.6yrs	sin datos	0% DKK 0
Lene Skole-Sorensen	Deputy Chairman	7.6yrs	sin datos	0.0021% DKK 102.5k
Jeffrey Berkowitz	Independent Director	4.4yrs	sin datos	sin datos
Lars Holmqvist	Director	7.6yrs	sin datos	0% DKK 0
Dorothea Wenzel	Independent Director	1.4yrs	sin datos	sin datos
Santiago Arroyo	Independent Director	1.4yrs	sin datos	sin datos
Camilla Andersson	Employee Representative Director	less than a year	sin datos	sin datos
Dorte Clausen	Employee Representative Director	less than a year	sin datos	sin datos
Hossein Armandi	Employee Representative Director	less than a year	sin datos	sin datos
Lasse Skibsbye	Employee Representative Director	less than a year	sin datos	sin datos

1.4yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de HLUY.Y no se considera experimentada (1.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

H. Lundbeck Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

H. Lundbeck A/S Common Stock to Be Deleted from OTC Equity

H. Lundbeck A/S Provides Earnings Guidance for the Year 2022

H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the Role of Vortioxetine

H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

H. Lundbeck A/S Proposes Dividend for the Year 2021

EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine in Adults

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder

H. Lundbeck A/S Appoints Tarek Samad as Head of Research, Effective on May 1, 2021

H. Lundbeck A/S Announces Resignation of Henrik Andersen from Board

Rigshospitalet and Lundbeck Announce Partnership to Find New Ways to Treat Brain Diseases

Lundbeck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Eptinezumab for the Prevention of Migraine

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2020

H. Lundbeck A/S Revises Earnings Guidance for the Year 2020

OVATION Pharmaceuticals, Inc. acquired Buronil from H. Lundbeck A/S.

H. Lundbeck A/S Presents Positive Data from the Complete Study with Vortioxetine

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad